Filing Flows › Editas Medicine (EDIT) › Q3 2025
Editas Medicine (EDIT) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 10, 2025
Editas Medicine (EDIT) reported revenue of $7.5M for the third quarter 2025 (Q3 2025), up 124-fold from a year earlier and +111% from the quarter before. Operating margin was -325.4%, net loss $25.1M (333.0% of revenue).
Editas Medicine, Q3 2025: revenue $7.5M (124× year over year), operating margin -325.4%, net loss $25.1M, operating cash flow −$30.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.5M | +111% | 124× |
| Operating profit | −$24.5M | — | — |
| Net earnings | −$25.1M | — | — |
| Operating cash flow | −$30.8M | — | — |
What changed
Revenue was $7.5M in Q3 2025, up 12266% year over year and up 111% from the previous quarter.
Operating costs exceeded revenue by $24.5M, an operating margin of -325.4%. Total costs fell 51% while revenue rose 12266%. The quarter ended with a net loss of $25.1M, narrower than the previous quarter's $53.2M loss.
Operating cash flow was −$30.8M. Non-cash charges added back $721K of depreciation and $2.2M of share-based compensation. Working capital and other items used $8.7M. Capital expenditures of $433K exceeded it, leaving free cash flow of −$31.3M.
Questions
What was Editas Medicine's revenue in the third quarter 2025?
Editas Medicine (EDIT) reported revenue of $7.5M for the third quarter 2025 (Q3 2025), up 124-fold from a year earlier and +111% from the quarter before.
Was Editas Medicine profitable in the third quarter 2025?
Operating loss was $24.5M (-325.4% of revenue) and net loss $25.1M.
Source: Editas Medicine 10-Q on SEC EDGAR.